Revolution Medicines Announces First Patient Randomized in the RASolute 304 Clinical Trial of Daraxonrasib in Resectable Pancreatic Ductal Adenocarcinoma Following Adjuvant Chemotherapy
FDA Breakthrough Status For Daraxonrasib Might Change The Case For Investing In Revolution Medicines (RVMD) [Yahoo! Finance]
Revolution Medicines (NASDAQ:RVMD) was upgraded by analysts at UBS Group AG to a "strong-buy" rating.
Healthcare stocks are red-hot. Here are 3 picks from a fund manager up 41% this year. [Business Insider]
Revolution Medicines (NASDAQ:RVMD) was upgraded by analysts at Wolfe Research to a "strong-buy" rating.